# Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

> **NCT02641522** · EARLY_PHASE1 · COMPLETED · sponsor: **Carla Greenbaum, MD** · enrollment: 10 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Siltuximab

## Key facts

- **NCT ID:** NCT02641522
- **Lead sponsor:** Carla Greenbaum, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-08
- **Primary completion:** 2017-03-16
- **Final completion:** 2017-03-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641522, "Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02641522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*